Ocular Therapeutix has received Medicare coverage earlier than expected for its ophthalmic device, the Dextenza dexamethasone ophthalmic insert 0.4mg.

The Centers for Medicare and Medicaid Services (CMS) handed the company’s insert a reimbursement J-code, enabling reimbursement for the device in offices and surgical centers. The code will become active on October 1.

The device is approved by the FDA for treating ocular inflammation and pain after ophthalmic surgery. The corticosteroid intracanalicular insert delivers dexamethasone to the surface of the eye for up to 30 days without preservatives.